The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Xeglyze
Synonyms :
abametapir
Class :
Topical Pediculicides
Dosage Forms & Strengths Â
lotion (topical)Â Â
0.74%Â Â Â
Recommended for use in the topical treatment of head lice infestation
Apply to dry hair in a quantity sufficient to completely cover the hair and scalp
Use as part of a comprehensive lice management programme:
Wash any recently used items, caps, used bedding, and towels in hot water or dry clean them
Wash personal care products in hot water, such as combs, brushes, and hair clips
Dead lice and nits should be removed with a fine-tooth comb or specialised nit comb
lotion (topical)Â Â
0.74%Â Â
Age: ≥6 months
Recommended for use in the topical treatment of head lice infestation
Apply to dry hair in a quantity sufficient to completely cover the hair and scalp
Use as part of a comprehensive lice management programme:
Wash any recently used items, caps, used bedding, and towels in hot water or dry clean them
Wash personal care products in hot water, such as combs, brushes, and hair clips
Dead lice and nits should be removed with a fine-tooth comb or specialised nit comb
Refer to the adult dosing regimenÂ
may enhance the serum concentration of abametapir
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
bunazosin (Not available in the United States)
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
may increase the serum concentration of epinastine when combined
may increase the serum concentration when combined with each other
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
It may enhance the effect when combined with sufentanil by affecting CYP3A4 metabolism
It may enhance the level when combined with efavirenz by affecting CYP3A4 metabolism
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be an increasing effect of alpelisib by affecting hepatic or intestinal enzyme cyp3a4 metabolism   
abametapir, when interacts with brentuximab vedotin, will increase its effect by altering the intestinal/hepatic metabolism of CYP3A4 enzyme the drugs containing substrates of CYP3A4 should be avoided during the medication.
when both drugs are combined, there may be an increased level of serum concentration of erlotinib  
the effect of abametapir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
abametapir increases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
abametapir increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
abametapir increases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
abametapir increases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
abametapir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
abametapir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of dronabinol by altering the intestinal or hepatic metabolism
when both drugs are combined, there may be an increased risk of adverse effects 
when both drugs are combined, there may be an increased risk of adverse effects 
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
it enhances by affecting the hepatic enzyme CYP2B6 metabolism
may increase the level of zonisamide by affecting the hepatic enzyme CYP3A4 metabolism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
relugolix/​estradiol/​norethindroneÂ
it enhances by affecting the hepatic enzyme CYP3A4 metabolism
abametapir affect the hepatic enzyme CYP1A2 metabolism to increase the level or effect of melatonin
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
The co-administration of abametapir has the potential to elevate the concentration serum of netupitant
abametapir with mibefradil may result in an enhance in the concentration serum of mibefradil
Combining antipyrine with abametapir may lead to an elevation in the concentration serum of antipyrine
When abametapir is used together with elbasvir, this leads to a rise in the concentration serum of elbasvir
When abametapir is used together with grazoprevir, this leads to a rise in the concentration serum of grazoprevir
abametapir: it may increase the serum concentration of lidoflazine
when combined with abametapir, there may be an increase in the serum concentration of ivacaftor
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
abametapir: it may increase the serum concentration of barnidipine
when both drugs are combined, there may be an increased the serum concentration of paclitaxel 
it may enhance the serum concentration when combined with azelastine
may increase the serum concentration when it is combined
anagrelide: they may increase the antiplatelet effect of antiparasitic agents
zanubrutinib: they may increase the antiplatelet effect of antiparasitic agents
It may enhance the risk of adverse effects when combined with platelet inhibitors
It may enhance the risk of adverse effects when combined with platelet inhibitors
It may enhance the risk of adverse effects when combined with platelet inhibitors
It may enhance the risk of adverse effects when combined with platelet inhibitors
It may enhance the risk of adverse effects when combined with platelet inhibitors
monitor for serum concentration of clonidine, which is increased when abametapir is used in combination
serum levels of telaprevir can be increased when combined with abametapir
the serum levels of fluocortolone may be raised when taken with abametapir
the serum levels of tocofersolan may be raised when taken with abametapir
combining asunaprevir with abametapir can raise its serum concentration
abametapir can increase the serum concentration of dihydroergocristine when combined with it
the serum levels of dihydrocodeine may be increased with abametapir
the serum levels of dihydroergocornine may be increased
the serum levels of norethynodrel may be increased
the sulfinpyrazone serum concentration can be raised when combined with abametapir
the coadministration of abametapir and prenylamine may result in an elevation of the serum concentration of prenylamine
the serum levels of cethromycin may be elevated
the serum concentration of fostamatinib can be increased when it is combined with abametapir
the serum levels of dydrogesterone may be increased
combining abametapir with diethylstilbestrol can raise its serum concentration in the blood
When abametapir is used together with oliceridine, this leads to enhanced concentration serum of oliceridine
the serum levels of methoxyflurane may be increased
When abametapir is used together with lomitapide, this leads to enhanced concentration serum of lomitapide.
the serum levels of zotepine may be raised when taken with abametapir
when combined with abametapir, the serum levels of bufylline can be enhanced
the flurandrenolide serum concentration can be elevated when combined with abametapir
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
abametapir is a topical insecticide indicated for treating patients with head lice infestation. It belongs to the metalloproteinase inhibitors class of drugs. It acts through inhibiting a crucial metalloproteinase enzyme in the head lice, which cause their death.Â
It is also effective against all stages of the head lice including those that have resistance to other products.Â
Frequency defined Â
1-10%Â Â
Hair color changes (1%)Â Â
Eye irritation (1.2-1.7%)Â Â
Contact dermatitis (1.7%)Â Â
Vomiting (1.7%)Â Â
Skin burning (2.6%)Â Â
edema/Scalp erythema (3.2%)Â Â
Rash (3.2%)Â Â
Erythema (4%)Â Â
Black Box Warning:Â Â
There is currently no black box warning for abametapir.
Contraindication/Caution:Â Â
Contraindication:Â Â
 CautionÂ
Pregnancy/Lactation Â
Pregnancy consideration: US FDA pregnancy category: Not assigned Â
Lactation: It is also not known if abametapir passes into breast milk Â
Pregnancy category:Â Â
PharmacologyÂ
It is an antiparasitic agent, which is used in the treatment of head lice. It acts through inhibiting crucial biochemical activities within the body of a louse that results in suffocating the insect.Â
PharmacodynamicsÂ
It is effective against all life-cycle stages of lice as it inactivates essential enzymes; the lotion is very potent and requires only one application due to its mode of action. Of its main metabolites, abametapir carboxyl has a half-life of about 71 hours and may inhibit some CYP450 enzymes, so they should not take any substrates of CYP3A4, CYP2B6, or CYP1A2 for 2 weeks after consumption. Abametapir lotion also contains benzyl alcohol which has been known to cause Systemic toxicity when absorbed through the skin especially to young infants.Â
Pharmacokinetics Â
Absorption Â
At its highest concentration, plasma concentration is reached within 0. 57 to 1.54 hours.Â
Distribution Â
The peak plasma concentration of abametapir varies by age:Â Â
In children 6 months to less than 1 year it ranges from 228 to 418 ng/mL, Â
the one with 1 to less than 2 years from 147 to 209 ng/mL, Â
the one with 2 to less than 3 years from 160 to 206 ng/mL, Â
and the one with 3 to 17 years from 52 to 121 ng/mL. Â
Â
Metabolism Â
Highly biotransformed, mainly with the help of CYP1A2 enzyme to the mono-hydroxylated metabolite (abametapir hydroxyl) and then to the mono-carboxylated metabolite (abametapir carboxyl).Â
Elimination and excretion Â
There is no direct data regarding the excretion of abametapir and its human metabolites.Â
Half-life:Â
Administration Â
It is used topically as a lotion and should be applied to dry hair and scalp with the lotion rubbing it in until the entire scalp and hair is covered with the lotion. The lotion should be applied on the skin and allowed to work for a minimum of 10 minutes before washing off with water.Â
Patient information leaflet Â
Generic Name: abametapir Â
Pronounced: (ab-a-MEH-ta-peer)Â Â
Why do we use abametapir? Â
abametapir is topical insecticide that is used in treating head lice infestation in adults and children, 6 months of age and older. It acts through the blocking of the function of an enzyme known as acetylcholinesterase which plays a significant role in the head lice nervous system. abametapir immobilizes and kills the lice due to paralysis, thus treating the infestation.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
